Secondary Logo

Journal Logo

Articles by Arun Swaminath

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Narula, Neeraj; Peerani, Farhad; Meserve, Joseph; More

The American Journal of Gastroenterology. 114(4):696, April 2019.

Shifts in Vedolizumab Utilization Across the United States Are Associated With Improved Outcomes: 583

Koliani-Pace, Jenna; Singh, Siddharth; Hirten, Robert; More

American Journal of Gastroenterology. 113:S335-S336, October 2018.

Perceptions on Shared Management and Primary Care Competencies in Inflammatory Bowel Disease (IBD) Care Informed Through a Gastroenterologist-Led Mentorship Model: 664

Cross, Ray Jr.; Ahmed, Tasneem; Chasen, Richard; More

American Journal of Gastroenterology. 113:S376, October 2018.

Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Narula, Neeraj; Peerani, Farhad; Meserve, Joseph; More

American Journal of Gastroenterology. 113(9):1345, September 2018.

Therapy Escalation in Patients With Inflammatory Bowel Disease FollowingClostridium difficileInfection Is not Associated With Adverse Clinical Outcomes: An IBD ReMEdY Study: 597

Lukin, Dana J.; Lawlor, Garrett; Hudesman, David P.; More

American Journal of Gastroenterology. 112:S321,S324, October 2017.

Real World Usage Patterns of Vedolizumab in Inflammatory Bowel Disease: Results From the VICTORY Consortium: 2017 Presidential Poster Award: 726

Dulai, Parambir S.; Koliani-Pace, Jenna L.; Chaudrey, Khadija; More

American Journal of Gastroenterology. 112:S400-S401, October 2017.

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

Dulai, Parambir S; Singh, Siddharth; Jiang, Xiaoqian; More

American Journal of Gastroenterology. 111(8):1147-1155, August 2016.

Show: